Öz
SüleymanDemirel Üniversitesi
TIP FAKÜLTESİ DERGİSİ: 2006 Eylül; 13(3)
Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin
plazma lipid düzeylerine etkisi
Ercan Varol, Mehmet Şahin, S Murat Aslan, Mehmet Özaydın, Ahmet Altınbaş
Özet
Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi
Kısa dönem, 1 aylık orlistat tedavisinin lipid profili üzerine etkisini araştırmak. Onüç obez hastada düşük kalorili diyete ilave olarak günde 3 kez 120 mg orlistat verildi. Başlangıç ve 1 ay sonraki plazma lipid düzeylerine bakıldı. Trigliserid (TG) seviyesi 169.9 ± 62.7 mg/dl den 156.6 ± 60.4 mg/dl'ye (p<0.05), düşük dansiteli lipoprotein kolesterol (LDL-K) seviyesi 137.7 ± 17.5 mg/dl den 136.1 ± 17.2 mg/dl'ye (p<0.05) ve total kolesterol (TK) seviyesi 222.1 ± 47.3 mg/dl den 220.8 ± 47.6 mg/dl seviyesine düştü (p<0.05). Azalmalar istatistiksel açıdan anlamlı idi. Yüksek dansiteli lipoprotein kolesterol (HDL-K) seviyesindeki artış anlamlı değildi (36.5 ± 2.7 mg/dl den 36.9 ± 2.4 mg/dl' ye; p=0.09). Orlistat kilo verdirici etkisinden bağımsız olarak 1 aylık kısa dönemde lipid profili üzerine olumlu etkiye sahiptir.
Anahtar kelımeler: Obezite, Orlistat, Kolesterol, Trigliserid
Abstract
Effect of short term (1 month) orlistat treatment on plasma lipid levels ın obese patients
The aim of the study is to investigate the effect of a short term 1–month orlistat treatment on lipid profile in obese patients. Orlistat was administered three times 120 mg in a day in conjunction with a reduced calorie diet in 13 obese patients. Plasma lipid levels were determined at beginning and 1 month later. The triglyceride level decreased from 169.9 ± 62.7 mg/dl to 156.6 ± 60.4 mg/dl (p<0.05), low density lipoprotein cholesterol level decreased from 137.7 ± 17.5 mg/dl to 136.1 ± 17.2 mg/dl (p<0.05) and total cholesterol level decreased from 222.1 ± 47.3 mg/dl to 220.8 ± 47.6 mg/dl (p<0.05). The changes were statistically significant. The increase in high density lipoprotein cholesterol levels was not statistically significant (36.5 ± 2.7 mg/dl to 36.9 ± 2.4 mg/dl; p=0.09). Orlistat has a beneficial effect on lipid profiles in 1 month short term period in obese patients regardless of weight loss.
Key words: Obesity, Orlistat, Cholesterol, Triglyceride
Anahtar Kelimeler
Kaynakça
- Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB & Patel IH Retrospective population- based analysis of the dose response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 8285.
- Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disorder 1997; 21 (suppl.3): S12S23
- Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP et al. Randomized placebo controlled trial of orlistat of weight loss and prevention of weight regain in obese patiants. Lancet 1998; 352; 167 172
- Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281: 235242.
- Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance and impaired cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8: 4961.
- Kelley DE, Bray GA, Pi-Sunyer. Clinical efficacy of orlistat therapy in owerweight and obese patients with insulin treated-type 2 diabetes: a 1-year randomized controlled trial . Diabetes Care 2002; 25: 1033-41.
- Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profili, in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Therapeutics 2003; 25: 1107-22.
- Muls E, Kolanowski J, Scheen E, Van Gaal L. The effects of orlistat on weight and serum lipids in obese patients with hypercholestrolemia: a randomized, double blind, placebo controlled, multicentre study. Int J Obes Relat Metab Disord 2001; 25: 1713-21
- Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet ( 30 % of calories from fat) on plasma lipids, glucose and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003; 91: 961964.
- Bloch KV, Salles KF, Muxfeldt ES, da Rocha Nogueria A. Orlistat in hypertensive overweight / obese patients: results of a randomized clinical trial. J Hypertens 2003; 21(11): 2159-65.
- van Greevenbroek MM, de Bruin TW. Chylomicron synthesis by intestinal cells in vitro and in vivo. Atherosclerosis 1998; 141(suppl 1): S9S16.
- Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of orlistat in the treatment of severe hypertriglyceridemia. Am J Cardiol 2002; 89: 22931.
- Mittendorfer B, Ostlund RE, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorbtion. Obes Res 2001; 9: 599-604
- Hutton B, Ferguson D. Changes in body weigth and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systemic rewiew of randomized clinical trials. Am J Clin Nutr 2004; 80: 1461-8
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Bölüm | Araştırma Makaleleri |
| Yazarlar | |
| Yayımlanma Tarihi | 21 Nisan 2009 |
| Gönderilme Tarihi | 20 Nisan 2009 |
| Yayımlandığı Sayı | Yıl 2006 Cilt: 13 Sayı: 3 |
Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi/Medical Journal of Süleyman Demirel University is licensed under Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International.